In particular, disease modifying anti-rheumatic drugs (DMARDs) are of interest in RA therapy, with most of them acting as IL-1/IL-6/IL-17/TNF-α inhibitors or B cell inhibitors (Hyndman, 2017; Guo et al., 2018). Here, IL1B is linked to rheumatoid arthritis.